Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions

Endocr Pathol. 2010 Jun;21(2):101-7. doi: 10.1007/s12022-010-9116-9.

Abstract

Thyroid cancer is the most frequent endocrine neoplasia worldwide. The route for metastasis and loco-regional invasion preferentially occurs by lymphatic vessels. For this reason, the assessment of lymphatic vessel density (LVD) is supposed to represent both a prognostic parameter and also a potential therapeutic target. In order to evaluate the value of LVD in benign and malignant thyroid lesions, we analyzed 110 thyroidectomy specimens using D2-40, a specific marker for lymphatic vessels and vascular endothelial growth factor C (VEGF-C), the most potent molecule of lymphatic proliferation. LVD was significantly different between papillary and follicular carcinomas in total (p = 0.045) and peritumoral area (p = 0.042). Follicular adenoma and follicular carcinoma showed an important difference of intra- (p = 0.019) and peritumoral (p = 0.033) LVD. VEGF-C was more markedly expressed in malignancies than in benign lesions (p = 0.0001). Almost all cancers with high positive VEGF-C expression also exhibited increased peritumoral LVD (p = 0.049) when compared with the benign lesions. Indeed, the high peritumoral LVD of malignant thyroid lesions is an important finding for surgery planning and supports the practice of total thyroidectomy in malignant thyroid neoplasm's since the lymphatic peritumoral vessels definitely are an escape path for tumor cells.

MeSH terms

  • Adenocarcinoma, Follicular / metabolism
  • Adenocarcinoma, Follicular / pathology
  • Adenocarcinoma, Papillary / metabolism
  • Adenocarcinoma, Papillary / pathology
  • Adenoma / metabolism
  • Adenoma / pathology
  • Adult
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor / analysis*
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Vessels / metabolism
  • Lymphatic Vessels / pathology*
  • Male
  • Middle Aged
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / pathology*
  • Vascular Endothelial Growth Factor C / biosynthesis*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor
  • Vascular Endothelial Growth Factor C
  • monoclonal antibody D2-40